CoChat

Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?

Hernigou, Philippe, Flouzat Lachaniette, Charles Henri, Delambre, Jerome, Chevallier, Nathalie, Rouard, Helene · 2014 · International Orthopaedics

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Abstract

Purpose There is concern that regenerative cell-based therapies at the site of malignant primary bone tumours could result in increased risk of local tumour recurrence. We therefore investigated the long-term risks for site-specific recurrences in patients who had received an autologous bone marrow derived mesenchymal stem cell suspension to improve healing at the host-to-allograft bone junction of the reconstruction after bone tumour resection. Methods A total of 92 patients were treated from 1993 to 2003 with bone marrow-derived mesenchymal stem cells after bone tumour resection. Patients were monitored for cancer incidence from the date of first operation (1993) until death, or until 31 December 2013. The mean follow-up time was 15.4 years (range ten to 20 years). The average number of MSCs returned to the patient was 234,000 MSCs ± 215,000. The primary outcome was to evaluate the risk of tumorigenesis recurrence at the cell therapy treatment sites with radiographs and/or MRIs. The relative risk of cancer recurrence was expressed as the ratio of observed and expected number of cases according to three different control populations. Results Thirteen recurrences were found at the treatment sites among the 92 patients. The expected number of recurrences based on incidence in the three cohort populations was between 15 and 20 for the same cancer, age and sex distribution. The standardized incidence ratio (equal to observed cancers divided by expected cancers) for the entire fo…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00264-014-2384-0

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Delepine G, Delepine N, Hernigou P (1991) Allograft with patellar tendon in reconstructive procedures after upper tibial resection. Limb Salvage Ed., Springer, pp 436–437
  2. Hernigou P, Beaujean F (1997) Autologous bone marrow to stimulate bone healing. J Cell Eng 2(3):113–116

Cited by

See all 22

Metadata

Authors
Hernigou, P., Flouzat Lachaniette, C. H., Delambre, J., Chevallier, N., & Rouard, H.
Affiliations
Centre Hospitalier Universitaire Henri-Mondor (FR)
Corresponding author
Hernigou, Philippe
Venue
International Orthopaedics
Published
2014-06-07
Volume
38
Issue
9
Pages
1825-1835
ISSN
  • 0341-2695 (ISSN-L)
  • 1432-5195
OpenAlex
W1965962463
Cited by
22
References
52
Citations by year
2024: 1 · 2023: 2 · 2021: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 1
FWCI
3.48
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Orthopaedics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
mesenchymal stem cells, bone tumor resection, local recurrence, carcinogenesis, autologous cell therapy, bone marrow-derived stem cells, bone reconstruction, cancer risk, long-term follow-up, standardized incidence ratio
MeSH terms
Adolescent, Adult, Bone Neoplasms, Bone Regeneration, Child, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, Time Factors, Incidence, Bone Transplantation, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.